改良VAD方案联合沙利度胺治疗多发性骨髓瘤被引量：1

Modified VAD regimen combined with thalidomide in treatment of multiple myeloma

导出

摘要目的:观察改良VAD方案联合沙利度胺治疗多发性骨髓瘤的临床疗效和不良反应。方法:12例多发性骨髓瘤均采用改良VAD方案联合沙利度胺治疗。沙利度胺的起始剂量为100mg/天,每周增加100mg,直至剂量增加至300mg/天。28天为1周期。治疗2个周期后,根据血象、血清M蛋白、血清肌酐、骨髓瘤细胞等指标来判断疗效,分为部分缓解、改善和无效。结果:部分缓解6例,改善4例,总有效率为83·3%。主要不良反应有嗜睡(75%)、便秘(50%)、头晕(25%)和感染(25%),但都能耐受。结论:改良VAD方案联合沙利度胺治疗多发性骨髓瘤具有疗效高和耐受性好的优点,尤其是对于有合并症的老年患者是安全的,值得进一步的临床观察和推广。 Objective：To observe the efficacy and side effects of modified VAD regimen combined with thalidomide in treatment of multiple myeloma. Methods：12 patients with multiple myeloma were administrated with modified VAD regimen combined with thalidomide. The initial dose of thalidomide was 100mg/d, then increased 50mg per day till the maximal tolorant dose. The therapeutic effectiveness was classified into partial remission, improvement and uneffective according to the change of serum M protein, creatine, bone marrow myeloma cell and paripheral blood counts. Results：The total response rate was 83.3% （ including 6 cases of partial remission, 4 cases of improvement ）. The main side effects were sleepiness （75%）, constipation （50%）, dizzy （25%） and infection （25%）, which all were tolerable. Conclusion ：The merits of modified VAD regimen combined with thalidomide in treatment of multiple myeloma are significant response rate, less side effects, good tolerance and safty, especially for elder patients with complications. It is worthy for clinical investigation and widespread generalization.

作者叶成林张伟民

机构地区上海市杨浦区市东医院血液科

出处《临床肿瘤学杂志》 CAS 2006年第6期431-433,439,共4页 Chinese Clinical Oncology

关键词多发性骨髓瘤改良VAD方案沙利度胺 Multiple myeloma Modified VAD regimen Thalidomide

分类号 R730.53 [医药卫生—肿瘤] R738.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1Kneller A,Ranani P,Hardan I,et al.Therapy with thalidomide in refractory multiple myeloma patients:the revival of an old drug[J].Br J Haematol,2000,108(2):391-393.
2Myeloma Trialists Collborative Group.Combination chemotherapy versus melplalan plus prednisone as treatment for multiple myeloma:an overview of 6633 patients from 27 randomized trials[J].J Clin Oncol,1998,16:3832-3880.
3Barlogie B,Johnston DA,Keating M,et al.Effective treatment of advanced multiple myeloma refractory to alkylating agents[J].N Engl J Med,1984,310(21):1353-1356.
4Anderson H,Sarffe JH,Lambert M,et al.VAD chemotherapy-toxicity and efficacy in patients with multiple myeloma and other lymphoid malignancies[J].Hematol oncol,1987,5(3):213-222.
5Singhal S,Mehta J,Desikan R,et al.Antimmor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341 (21):1565.
6Raje NR,Anderson K.Thalidomide a revival story[J].N Engl J Med,1999,341:1606.
7Mc carty MF.Thalidomide may inpede cell migtation in primates by down-regulating intergrin beta-chains:potential therapeutic utility in solid malignancies,proliferative retinopathy,inflammatory disorders,neoinitial hyoerpasis,and osteoporosis[J].Med Hypotheses,1997,49(2):123.
8Fermandez LP,Schlegel PG,Baker J,et al.Does thalidomide affect IL-2 response and production?[J].EXP Hematol,1995,23 (9):978.
9Singhal S,Mehta J.Thalidomide in cancer[J].Biomed pharmacother,2002,56(1):4-12.
10Hideshima T,Chauhan D,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J].Blood,2000,96(9):2943-2950.